Chronic Immune Thrombocytopenia Market Size|Industry Trends|Market Insights|Market Forecast 2026
The Global Chronic Immune Thrombocytopenia Market size was worth $ XX billion in 2019 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).
(EMAILWIRE.COM, October 17, 2019 ) Market Overview:
Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production.
Market Dynamics:
Growing demand for therapeutics for the treatment of rare blood related disorders, and increasing number of products approved by the Food and Drug Administration are some of the major factors driving the growth of the chronic immune thrombocytopenia (ITP) market globally. According to National Organization of Rare Disorders (NORD), the incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000 adults/year. The prevalence is 9.5 cases per 100,000.
Several pharmaceutical companies conducting research in rare diseases arena have received approvals from the FDA recently which is boosting the growth of the chronic immune thrombocytopenia market. For instance, in June 2019, the FDA approved Avatrombopag (Doptelet, Dova Pharmaceuticals) for the treatment of adults with chronic immune thrombocytopenia.
However, despite the increasing use of Thrombopoietin Receptor Agonist (TPO-RA), many patients remain refractory to available treatments. Current research is focused on combining therapies to address multiple mechanisms of disease simultaneously which may result into which may result into improved response rates and less toxicity.
Market Segmentation:
On the basis of drug class, the Chronic Immune Thrombocytopenia Market is segmented into Immunoglobulin, Thrombopoetin (TPO) Receptor Agonist, Steroids, Platlet Stimulating Agents, and others. Among these, Steroids holds significant market share in 2018 and estimated to grow at a CAGR of 5.74% during the forecast period. There are two main types of steroids: corticosteroids and anabolic-androgenic steroids (or anabolics for short).
Chronic ITP is cured either when the platelet count falls below 30,000, or when there is bleeding. A steroid (such as prednisone) is the first treatment; if steroids do not keep the platelet count above 50,000, then it is treated with intravenous gamma globulin. If these treatments are not effective and the platelet count remains dangerously low or there is bleeding, other options such as removal of the spleen (splenectomy), treatment with rituximab (Rituxan), Romiplostim (Nplate) or Eltrombopag (Promacta, Revolade) are preferred.
Geographical Analysis:
By geography, the Market is segmented into North America, Asia-Pacific (APAC), Europe, South America, and the Middle East and Africa (MEA).
North America holds the dominant market share for Chronic Immune Thrombocytopenia in 2018, and it is expected to maintain the growth over the forecast period, owing to the rising prevalence of immune thrombocytopenia, availability of treatment options and existence of effective reimbursement policies.
The Europe Chronic ITP market is also growing at a significant CAGR during the forecast period, due to increasing cases of chronic ITP coupled with rising research activities for the treatment of chronic ITP. The European Medicines Agency (EMEA) has recognized chronic immune thrombocytopenia (ITP) as an orphan disease, with nearly 50,000 adult patients with chronic ITP in the European Union.
Competitive Analysis:
Some of the major players in the chronic immune thrombocytopenia market are: Novartis AG, Dova Pharmaceuticals, F.Hoffmann-La Roche Ltd., CSL Limited, Amgen Inc., Kyowa Hakko Kirin Co., Ltd., Shionogi Inc., Rigel Pharmaceuticals, Inc., Jiangsu Hengrui Pharmaceutical Co., Ltd., and Shire and Ligand Pharmaceuticals, Inc.
Download free sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market
View full report: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: pr@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production.
Market Dynamics:
Growing demand for therapeutics for the treatment of rare blood related disorders, and increasing number of products approved by the Food and Drug Administration are some of the major factors driving the growth of the chronic immune thrombocytopenia (ITP) market globally. According to National Organization of Rare Disorders (NORD), the incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000 adults/year. The prevalence is 9.5 cases per 100,000.
Several pharmaceutical companies conducting research in rare diseases arena have received approvals from the FDA recently which is boosting the growth of the chronic immune thrombocytopenia market. For instance, in June 2019, the FDA approved Avatrombopag (Doptelet, Dova Pharmaceuticals) for the treatment of adults with chronic immune thrombocytopenia.
However, despite the increasing use of Thrombopoietin Receptor Agonist (TPO-RA), many patients remain refractory to available treatments. Current research is focused on combining therapies to address multiple mechanisms of disease simultaneously which may result into which may result into improved response rates and less toxicity.
Market Segmentation:
On the basis of drug class, the Chronic Immune Thrombocytopenia Market is segmented into Immunoglobulin, Thrombopoetin (TPO) Receptor Agonist, Steroids, Platlet Stimulating Agents, and others. Among these, Steroids holds significant market share in 2018 and estimated to grow at a CAGR of 5.74% during the forecast period. There are two main types of steroids: corticosteroids and anabolic-androgenic steroids (or anabolics for short).
Chronic ITP is cured either when the platelet count falls below 30,000, or when there is bleeding. A steroid (such as prednisone) is the first treatment; if steroids do not keep the platelet count above 50,000, then it is treated with intravenous gamma globulin. If these treatments are not effective and the platelet count remains dangerously low or there is bleeding, other options such as removal of the spleen (splenectomy), treatment with rituximab (Rituxan), Romiplostim (Nplate) or Eltrombopag (Promacta, Revolade) are preferred.
Geographical Analysis:
By geography, the Market is segmented into North America, Asia-Pacific (APAC), Europe, South America, and the Middle East and Africa (MEA).
North America holds the dominant market share for Chronic Immune Thrombocytopenia in 2018, and it is expected to maintain the growth over the forecast period, owing to the rising prevalence of immune thrombocytopenia, availability of treatment options and existence of effective reimbursement policies.
The Europe Chronic ITP market is also growing at a significant CAGR during the forecast period, due to increasing cases of chronic ITP coupled with rising research activities for the treatment of chronic ITP. The European Medicines Agency (EMEA) has recognized chronic immune thrombocytopenia (ITP) as an orphan disease, with nearly 50,000 adult patients with chronic ITP in the European Union.
Competitive Analysis:
Some of the major players in the chronic immune thrombocytopenia market are: Novartis AG, Dova Pharmaceuticals, F.Hoffmann-La Roche Ltd., CSL Limited, Amgen Inc., Kyowa Hakko Kirin Co., Ltd., Shionogi Inc., Rigel Pharmaceuticals, Inc., Jiangsu Hengrui Pharmaceutical Co., Ltd., and Shire and Ligand Pharmaceuticals, Inc.
Download free sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market
View full report: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: pr@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results